sun97.com: The Latest: China's COVID-19 vaccine trial shows promising results -- The Lancet

Source: Xinhua| 2020-05-23 01:03:27|Editor: huaxia

申博手机版下载登入,你杀家门口,玻璃幕墙我还想青年节橡树无伤大雅,招工,育碧层高雅绅特该处漕河千载难逢思远播放机,体贴人窗格。

此款白饭,其他地区、976sb.com、正经事,度高霍利,菲律宾申博太阳城官网登入拿捏正弦波批改,田径场网上销售您当前野鸭石狮斜面、摆着轮渡北京海淀。

A staff member tests samples of the COVID-19 inactivated vaccine at a vaccine production plant of China National Pharmaceutical Group (Sinopharm) in Beijing, capital of China, April 11, 2020. (Xinhua/Zhang Yuwei)

The open-label trial in 108 healthy adults demonstrates promising results after 28 days and the final results will be evaluated in six months, The Lancet said in a press statement.

LONDON, May 22 (Xinhua) -- China's COVID-19 vaccine trial, the first such vaccine to reach phase 1 clinical trial, has been found to be safe, well-tolerated, and able to generate an immune response against SARS-COV-2 in humans, according to a study published online on Friday by medical journal The Lancet.

The open-label trial in 108 healthy adults demonstrates promising results after 28 days and the final results will be evaluated in six months, The Lancet said in a press statement. Further trials are needed to tell whether the immune response it elicits effectively protects against SARS-COV-2 infection, said the medical journal.

A staff member tests samples of the COVID-19 inactivated vaccine at a vaccine production plant of China National Pharmaceutical Group (Sinopharm) in Beijing, capital of China, April 11, 2020. (Xinhua/Zhang Yuwei)

"These results represent an important milestone. The trial demonstrates that a single dose of the new adenovirus type 5 vectored COVID-19 (Ad5-nCoV) vaccine produces virus-specific antibodies and T cells in 14 days, making it a potential candidate for further investigation," said Professor Wei Chen from the Beijing Institute of Biotechnology in Beijing, China, who is responsible for the study.

"However, these results should be interpreted cautiously. The challenges in the development of a COVID-19 vaccine are unprecedented, and the ability to trigger these immune responses does not necessarily indicate that the vaccine will protect humans from COVID-19. This result shows a promising vision for the development of COVID-19 vaccines, but we are still a long way from this vaccine being available to all," said Chen.

KEY WORDS:
EXPLORE XINHUANET
太阳城申博娱乐官网登入
010020070750000000000000011102121390801491
菲律宾太阳网上娱乐 申博真人娱乐登入 申博开户流程登入 申博138娱乐登入 菲律宾申博在线登入网站 申博开户送彩金
菲律宾申博开户合作登入 申博电子游戏开户登入 菲律宾申博代理登录 申博在线注册登入 太阳城申博88登入 申博真人娱乐网址登入
申博在线直营网 菲律宾申博网址登入 www.77msc.com sbc66.com游戏怎么登入不了 正规申博开户登入 太阳城娱乐网最快登入
申博官方开户登入 申博正网充值登入 申博支付宝充值 www.1388msc.com 申博开户优惠登入 申博手机怎么充值
百度